ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial Phase 1 clinical data for ADX ...

Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria ...

RNA COVID-19 vaccines — originally developed to protect against the coronavirus — may be providing an additional, unexpected health advantage.

Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR =0.5 g/g) achieved in one-third of pat ...

FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data –– Gazyva is the only anti-CD20 monoclonal antibody to demonstrate a ...

Cancer patients who received a Covid-19 mRNA vaccine shortly after starting immunotherapy lived significantly longer than ...

Nestled between the busy roads of Kigali’s Remera and Ndera sectors, Nyandungu Ecopark feels like another world. The air is cleaner here, softer somehow. The city noise fades into the rustle of ...